| Publications | PubMed=11417493; DOI=10.1038/sj.leu.2402120
Takahashi H., Goto H., Funabiki T., Fujii H., Yamazaki S., Fujioka K., Ikuta K., Kai S.
Expression of two types of E2A-HLF fusion proteins in YCUB-2, a novel cell line established from B-lineage leukemia with t(17;19).
Leukemia 15:995-997(2001) PubMed=19157546; DOI=10.1016/j.leukres.2008.12.003
Goto H., Naruto T., Tanoshima R., Kato H., Yokosuka T., Yanagimachi M., Fujii H., Yokota S., Komine H.
Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children.
Leuk. Res. 33:1386-1391(2009) PubMed=20147975; DOI=10.1038/leu.2010.8
Akahane K., Inukai T., Inaba T., Kurosawa H., Look A.T., Kiyokawa N., Fujimoto J., Goto H., Endo M., Zhang X., Hirose K., Kuroda I., Honna H., Kagami K., Goi K., Nakazawa S., Sugita K.
Specific induction of CD33 expression by E2A-HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor.
Leukemia 24:865-869(2010) PubMed=20519628; DOI=10.1182/blood-2009-09-244673
Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H., Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H., Akahane K., Zhang X.-C., Kuroda I., Honna H., Kagami K., Goi K., Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.
Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
Blood 116:962-970(2010) PubMed=20575032; DOI=10.1002/ajh.21738; PMCID=PMC7159455
Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I., Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i., Tada M., Moriuchi T., Sugita K.
A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.
Am. J. Hematol. 85:535-537(2010) PubMed=29786757; DOI=10.1007/s12185-018-2474-7
Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H., Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T., Sugita K., Hosoi H.
Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
Int. J. Hematol. 108:312-318(2018) PubMed=32144432; DOI=10.1007/s00280-020-04045-9
Goto H., Yoshino Y., Ito M., Nagai J.-i., Kumamoto T., Inukai T., Sakurai Y., Miyagawa N., Keino D., Yokosuka T., Iwasaki F., Hamanoue S., Shiomi M., Goto S.
Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
Cancer Chemother. Pharmacol. 85:773-783(2020) PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068
Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C., Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H., Minegishi M., Iwamoto S., Sugita K., Inukai T.
Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022) |
|---|
